这家总部位于康涅狄格州吉尔福德的公司成立于2021年，原计划在纳斯达克上市，股票代码为INAI。 ThinkEquity原定为该交易的独家账簿管理人。 来源：智通财经网 开发炎症性疾病口服小分子药物的临床阶段生物科技公司Invea Therapeutics(INAI.US)于上周五以市场状 况为由，撤回了其美股首次公开募股计划。该公司此前提交的招股书显示，拟以每股10至12美元的价格 发行320万股，募资3500万美元。 ...

智通财经APP获悉，开发炎症性疾病口服小分子药物的临床阶段生物科技公司Invea Therapeutics(INAI.US)于上周五以市场状况为由，撤回了其美股首次公开募股计划。该公司此前提交的 招股书显示，拟以每股10至12美元的价格发行320万股，募资3500万美元。 这家总部位于康涅狄格州吉尔福德的公司成立于2021年，原计划在纳斯达克上市，股票代码为INAI。 ThinkEquity原定为该交易的独家账簿管理人。 ...

2026 年 03 月 08 日 行业研究 评级：推荐(维持) | 研究所： | | | --- | --- | | 证券分析师： | 董伯骏 S0350521080009 | | | dongbj@ghzq.com.cn | | 证券分析师： | 李永磊 S0350521080004 | | | liyl03@ghzq.com.cn | | 证券分析师： | 杨仁文 S0350521120001 | | | yangrw@ghzq.com.cn | | 联系人 ： | 曾子华 S0350124080006 | | | zengzh@ghzq.com.cn | [Table_Title] 2025 年我国基础研究投入占比创新高， Micro LED CPO 有望成为光互连替代方案 ——新材料产业周报 最近一年走势 | 行业相对表现 | | | 2026/03/06 | | --- | --- | --- | --- | | 表现 | 1M | 3M | 12M | | 基础化工 | 7.4% | 23.6% | 50.8% | | 沪深 300 | 0.4% | 1.7% | 17.8% | 相关报告 《新材 ...

王文涛表示，在服务消费领域，我们要推动对外开放和对内放开。以服务业为重点，扩大市场准入，推动增值电信、生物技术、外商独资医院等领域开放试点，清 理国内服务领域的不合理限制措施，扩大优质服务供给。 王文涛：我国网剧在全球市场营收占比达90% 王文涛表示，我国现在网剧在全球市场的营收占比达90%，APP下载量占全球80%，基本上我们国内看什么网剧，海外就看什么，只不过换了一下（形式）。 3月6日下午3时，十四届全国人大四次会议举行经济主题记者会，国家发展和改革委员会主任郑栅洁、财政部部长蓝佛安、商务部部长王文涛、中国人民银行行 长潘功胜、中国证券监督管理委员会主席吴清就发展改革、财政预算、商务、金融证券等相关问题回答中外记者提问。 会议上，商务部部长王文涛表示，商务部将坚持惠民生和促消费相结合，坚持政策和活动双轮驱动，深入实施提振消费专项行动，全力促消费扩内需。 王文涛："十四五"时期我国人均消费GDP从1万美元增至1.3万美元 王文涛表示，"十四五"时期，我国人均消费GDP从1万美元增至1.3万美元，居民消费呈现趋势性变化。传统消费从原来的短缺转变为优质、绿色低碳消费。从结构 看，服务消费特别是体验式消费增长强 ...

在十四届全国人大四次会议经济主题记者会上，商务部部长王文涛表示，商务部将坚持惠民生和促消费相结合，坚持政策和活动双轮驱动，深入实 施提振消费专项行动，全力促消费扩内需。 推动增值电信、生物技术、外商独资医院等领域开放试点 王文涛表示，在服务消费领域，我们要推动对外开放和对内放开。以服务业为重点，扩大市场准入，推动增值电信、生物技术、外商独资医院等领 域开放试点，清理国内服务领域的不合理限制措施，扩大优质服务供给。 "十四五"时期我国消费市场规模按购买力平价换算世界第一 王文涛说，"十四五"时期，我国消费市场规模稳居全球第二，以购买力平价换算，已经是世界第一。居民消费结构出现了一些趋势性的新变化。 ...

Invivyd (NasdaqGM:IVVD) Q4 2025 Earnings call March 05, 2026 08:30 AM ET Company ParticipantsBill Duke - CFOKatie Falzone - Senior VP of FinanceMarc Elia - Chairman of the Board of DirectorsRobert Allen - Chief Scientific OfficerTim Lee - Chief Commercial OfficerConference Call ParticipantsPatrick Trucchio - Biotechnology AnalystTom Schroeder - AnalystOperatorGood day. Thank you for standing by. Welcome to the Invivyd fourth quarter 2025 earnings conference call. At this time, all participants are on a list ...

Core Insights - Natera has recently announced its Q4 results, which were well received and set expectations for 2026 [1] - The company experienced significant revenue growth in the quarter, with record volumes for Signatera and strong gross margins [2] Financial Performance - In Q4, Natera achieved a gross margin of approximately 67%, which adjusted for true-ups, was close to 64% [2] - The company reported record absolute volumes and growth units for Signatera, indicating robust demand and operational performance [2]

ImmunityBio (NasdaqGS:IBRX) Q4 2025 Earnings call March 03, 2026 04:30 PM ET Company ParticipantsClara Dong - VP, Equity Research in BiotechnologyJason Kolbert - Managing Director, Head of Equity ResearchPatrick Soon-Shiong - Founder, Executive Chairman, and Global Chief Scientific and Medical OfficerRichard Adcock - President and CEOConference Call ParticipantsAndres Maldonado - Senior Biotechnology AnalystJeet Mukherjee - VP and Biotechnology AnalystTed Tenthoff - Biotech Equity Research AnalystOperatorGo ...

Investment Rating - The report maintains a positive investment rating for BeiGene, indicating a favorable outlook for the company's future performance [3]. Core Insights - BeiGene's Q4 2025 performance showed a strong sales growth of 32.8% year-over-year, reaching $1.498 billion, surpassing market expectations. However, net profit was impacted by a one-time impairment charge [3][4]. - The management projects 2026 sales to be between $6.2 billion and $6.4 billion, reflecting an approximate 20% year-over-year growth [3][4]. - The report highlights several upcoming catalysts for the company, including the global approval of the BCL-2 inhibitor sonrotoclax and ongoing clinical trials for other key products [5][6]. Summary by Relevant Sections Financial Performance - In Q4 2025, BeiGene reported a revenue increase of 32.8% to $1.498 billion, driven primarily by the sales of Brukinsa, which grew by 38.4% to $1.146 billion. The net profit was $67 million, a recovery from a loss of $152 million in Q4 2024, although it fell short of expectations due to a one-time equity investment impairment [4]. Product Pipeline - The BCL-2 inhibitor sonrotoclax received global approval for treating relapsed/refractory mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) in early 2026. The FDA's decision for MCL is expected in the first half of 2026. The company is also advancing its clinical trials for other products, including BTK CDAC BGB-16673 and CDK4 inhibitor BGB-43395 [5][6]. Market Position - BeiGene is positioned as a global biotechnology company based in China, focusing on developing innovative and affordable cancer therapies. Its robust global R&D and commercialization framework provides a competitive advantage in the industry [9]. Shareholder Information - As of February 27, 2026, BeiGene's stock price was $316.99, with a market capitalization of $39.49 billion. The stock has a consensus target price of $401.54, indicating potential upside [12].

Ionis Pharmaceuticals (NasdaqGS:IONS) FY Conference March 02, 2026 10:30 AM ET Company ParticipantsBrett Monia - CEOConference Call ParticipantsYaron Werber - AnalystYaron WerberOkay. Well, good morning, everybody, and thank you for joining us for the 46th annual TD Cowen Healthcare Conference. I'm Yaron Werber from the biotech team, and it's really a great pleasure to moderate the next fireside chat with Brett Monia, Chief Executive Officer of Ionis. Brett, good to see you.Brett MoniaGood to see you, Yaron ...